0	8	Coupling	coupling	NN
9	11	of	of	IN
12	13	a	a	DT
14	20	signal	signal	NN
21	29	response	response	NN
30	36	domain	domain	NN
37	39	in	in	IN
40	41	I	i	NN
42	47	kappa	kappa	NN
48	49	B	B	NNP
50	55	alpha	alpha	NN
56	58	to	to	TO
59	67	multiple	multiple	JJ
68	76	pathways	pathway	NNS
77	80	for	for	IN
81	89	NF-kappa	NF-kappa	NNP
90	91	B	B	NNP
92	102	activation	activation	NN
102	103	.	.	.

105	108	The	the	DT
109	119	eukaryotic	eukaryotic	JJ
120	133	transcription	transcription	NN
134	140	factor	factor	NN
141	149	NF-kappa	NF-kappa	NNP
150	151	B	B	NNP
152	157	plays	play	VBZ
158	159	a	a	DT
160	167	central	central	JJ
168	172	role	role	NN
173	175	in	in	IN
176	179	the	the	DT
180	187	induced	induce	VBN
188	198	expression	expression	NN
199	201	of	of	IN
202	207	human	human	JJ
208	224	immunodeficiency	immunodeficiency	NN
225	230	virus	virus	NN
231	235	type	type	NN
236	237	1	1	CD
238	241	and	and	CC
242	244	in	in	IN
245	249	many	many	JJ
250	257	aspects	aspect	NNS
258	260	of	of	IN
261	264	the	the	DT
265	272	genetic	genetic	JJ
273	280	program	program	NN
281	290	mediating	mediate	VBG
291	297	normal	normal	JJ
298	304	T-cell	t-cell	NN
305	315	activation	activation	NN
316	319	and	and	CC
320	326	growth	growth	NN
326	327	.	.	.

328	331	The	the	DT
332	339	nuclear	nuclear	JJ
340	348	activity	activity	NN
349	351	of	of	IN
352	360	NF-kappa	NF-kappa	NNP
361	362	B	B	NNP
363	365	is	be	VBZ
366	373	tightly	tightly	RB
374	383	regulated	regulate	VBN
384	388	from	from	IN
389	392	the	the	DT
393	404	cytoplasmic	cytoplasmic	JJ
405	416	compartment	compartment	NN
417	419	by	by	IN
420	422	an	an	DT
423	433	inhibitory	inhibitory	JJ
434	441	subunit	subunit	NN
442	448	called	call	VBN
449	450	I	i	NN
451	456	kappa	kappa	NN
457	458	B	B	NNP
459	464	alpha	alpha	NN
464	465	.	.	.

466	470	This	this	DT
471	482	cytoplasmic	cytoplasmic	JJ
483	492	inhibitor	inhibitor	NN
493	495	is	be	VBZ
496	503	rapidly	rapidly	RB
504	518	phosphorylated	phosphorylate	VBN
519	522	and	and	CC
523	531	degraded	degrade	VBN
532	534	in	in	IN
535	543	response	response	NN
544	546	to	to	TO
547	548	a	a	DT
549	556	diverse	diverse	JJ
557	560	set	set	NN
561	563	of	of	IN
564	572	NF-kappa	NF-kappa	NNP
573	583	B-inducing	b-inducing	JJ
584	590	agents	agent	NNS
590	591	,	,	,
592	601	including	include	VBG
602	608	T-cell	t-cell	NN
609	617	mitogens	mitogen	NNS
617	618	,	,	,
619	634	proinflammatory	proinflammatory	JJ
635	644	cytokines	cytokine	NNS
644	645	,	,	,
646	649	and	and	CC
650	655	viral	viral	JJ
656	671	transactivators	transactivator	NNS
672	676	such	such	JJ
677	679	as	as	IN
680	683	the	the	DT
684	687	Tax	Tax	NNP
688	695	protein	protein	NN
696	698	of	of	IN
699	704	human	human	JJ
705	711	T-cell	t-cell	NN
712	720	leukemia	leukemia	NN
721	726	virus	virus	NN
727	731	type	type	NN
732	733	1	1	CD
733	734	.	.	.

735	737	To	to	TO
738	745	explore	explore	VB
746	751	these	these	DT
752	753	I	i	NN
754	759	kappa	kappa	NN
760	761	B	B	NNP
762	777	alpha-dependent	alpha-dependent	JJ
778	788	mechanisms	mechanism	NNS
789	792	for	for	IN
793	801	NF-kappa	NF-kappa	NNP
802	803	B	B	NNP
804	813	induction	induction	NN
813	814	,	,	,
815	817	we	we	PRP
818	828	identified	identify	VBD
829	834	novel	novel	JJ
835	842	mutants	mutant	NNS
843	845	of	of	IN
846	847	I	i	NN
848	853	kappa	kappa	NN
854	855	B	B	NNP
856	861	alpha	alpha	NN
862	866	that	that	WDT
867	875	uncouple	uncouple	VBP
876	879	its	its	PRP$
880	890	inhibitory	inhibitory	JJ
891	894	and	and	CC
895	913	signal-transducing	signal-transducing	JJ
914	923	functions	function	NNS
924	926	in	in	IN
927	932	human	human	JJ
933	934	T	t	NN
935	946	lymphocytes	lymphocyte	NNS
946	947	.	.	.

948	960	Specifically	specifically	RB
960	961	,	,	,
962	969	removal	removal	NN
970	972	of	of	IN
973	976	the	the	DT
977	987	N-terminal	n-terminal	JJ
988	990	36	36	CD
991	996	amino	amino	NN
997	1002	acids	acid	NNS
1003	1005	of	of	IN
1006	1007	I	i	NN
1008	1013	kappa	kappa	NN
1014	1015	B	B	NNP
1016	1021	alpha	alpha	NN
1022	1028	failed	fail	VBD
1029	1031	to	to	TO
1032	1039	disrupt	disrupt	VB
1040	1043	its	its	PRP$
1044	1051	ability	ability	NN
1052	1054	to	to	TO
1055	1059	form	form	VB
1060	1066	latent	latent	JJ
1067	1076	complexes	complex	NNS
1077	1081	with	with	IN
1082	1090	NF-kappa	NF-kappa	NNP
1091	1092	B	B	NNP
1093	1095	in	in	IN
1096	1099	the	the	DT
1100	1109	cytoplasm	cytoplasm	NN
1109	1110	.	.	.

1111	1118	However	however	RB
1118	1119	,	,	,
1120	1124	this	this	DT
1125	1133	deletion	deletion	NN
1134	1142	mutation	mutation	NN
1143	1152	prevented	prevent	VBD
1153	1156	the	the	DT
1157	1164	induced	induce	VBN
1165	1180	phosphorylation	phosphorylation	NN
1180	1181	,	,	,
1182	1193	degradative	degradative	JJ
1194	1198	loss	loss	NN
1198	1199	,	,	,
1200	1203	and	and	CC
1204	1214	functional	functional	JJ
1215	1222	release	release	NN
1223	1225	of	of	IN
1226	1227	I	i	NN
1228	1233	kappa	kappa	NN
1234	1235	B	B	NNP
1236	1241	alpha	alpha	NN
1242	1246	from	from	IN
1247	1255	NF-kappa	NF-kappa	NNP
1256	1257	B	B	NNP
1258	1260	in	in	IN
1261	1275	Tax-expressing	tax-expressing	JJ
1276	1281	cells	cell	NNS
1281	1282	.	.	.

1283	1290	Alanine	Alanine	NNP
1291	1304	substitutions	substitution	NNS
1305	1315	introduced	introduce	VBN
1316	1318	at	at	IN
1319	1322	two	two	CD
1323	1329	serine	serine	NN
1330	1338	residues	residue	NNS
1339	1349	positioned	position	VBN
1350	1356	within	within	IN
1357	1361	this	this	DT
1362	1372	N-terminal	n-terminal	JJ
1373	1383	regulatory	regulatory	JJ
1384	1390	region	region	NN
1391	1393	of	of	IN
1394	1395	I	i	NN
1396	1401	kappa	kappa	NN
1402	1403	B	B	NNP
1404	1409	alpha	alpha	NN
1410	1414	also	also	RB
1415	1422	yielded	yield	VBD
1423	1435	constitutive	constitutive	JJ
1436	1446	repressors	repressor	NNS
1447	1451	that	that	WDT
1452	1459	escaped	escape	VBD
1460	1464	from	from	IN
1465	1476	Tax-induced	tax-induced	JJ
1477	1485	turnover	turnover	NN
1486	1489	and	and	CC
1490	1494	that	that	IN
1495	1503	potently	potently	RB
1504	1513	inhibited	inhibit	VBD
1514	1520	immune	immune	JJ
1521	1531	activation	activation	NN
1532	1540	pathways	pathway	NNS
1541	1544	for	for	IN
1545	1553	NF-kappa	NF-kappa	NNP
1554	1555	B	B	NNP
1556	1565	induction	induction	NN
1565	1566	,	,	,
1567	1576	including	include	VBG
1577	1582	those	those	DT
1583	1592	initiated	initiate	VBN
1593	1597	from	from	IN
1598	1605	antigen	antigen	NN
1606	1609	and	and	CC
1610	1618	cytokine	cytokine	NN
1619	1628	receptors	receptor	NNS
1628	1629	.	.	.

1630	1632	In	in	IN
1633	1641	contrast	contrast	NN
1641	1642	,	,	,
1643	1655	introduction	introduction	NN
1656	1658	of	of	IN
1659	1660	a	a	DT
1661	1674	phosphoserine	phosphoserine	NN
1675	1682	mimetic	mimetic	NN
1683	1685	at	at	IN
1686	1691	these	these	DT
1692	1697	sites	site	NNS
1698	1707	rectified	rectify	VBD
1708	1712	this	this	DT
1713	1723	functional	functional	JJ
1724	1730	defect	defect	NN
1730	1731	,	,	,
1732	1733	a	a	DT
1734	1741	finding	finding	NN
1742	1752	consistent	consistent	JJ
1753	1757	with	with	IN
1758	1759	a	a	DT
1760	1766	causal	causal	JJ
1767	1774	linkage	linkage	NN
1775	1782	between	between	IN
1783	1786	the	the	DT
1787	1802	phosphorylation	phosphorylation	NN
1803	1809	status	status	NN
1810	1813	and	and	CC
1814	1825	proteolytic	proteolytic	JJ
1826	1835	stability	stability	NN
1836	1838	of	of	IN
1839	1843	this	this	DT
1844	1855	cytoplasmic	cytoplasmic	JJ
1856	1865	inhibitor	inhibitor	NN
1865	1866	.	.	.

1867	1875	Together	together	RB
1875	1876	,	,	,
1877	1882	these	these	DT
1883	1885	in	in	FW
1886	1890	vivo	vivo	FW
1891	1898	studies	study	NNS
1899	1905	define	define	VBP
1906	1907	a	a	DT
1908	1916	critical	critical	JJ
1917	1923	signal	signal	NN
1924	1932	response	response	NN
1933	1939	domain	domain	NN
1940	1942	in	in	IN
1943	1944	I	i	NN
1945	1950	kappa	kappa	NN
1951	1952	B	B	NNP
1953	1958	alpha	alpha	NN
1959	1963	that	that	WDT
1964	1976	coordinately	coordinately	RB
1977	1985	controls	control	VBZ
1986	1989	the	the	DT
1990	1998	biologic	biologic	JJ
1999	2009	activities	activity	NNS
2010	2012	of	of	IN
2013	2014	I	i	NN
2015	2020	kappa	kappa	NN
2021	2022	B	B	NNP
2023	2028	alpha	alpha	NN
2029	2032	and	and	CC
2033	2041	NF-kappa	NF-kappa	NNP
2042	2043	B	B	NNP
2044	2046	in	in	IN
2047	2055	response	response	NN
2056	2058	to	to	TO
2059	2064	viral	viral	JJ
2065	2068	and	and	CC
2069	2075	immune	immune	JJ
2076	2083	stimuli	stimulus	NNS
2083	2084	.	.	.